Patent application number | Description | Published |
20130103592 | Interactive Licensing Of Media With Negotiation And Dynamic Pricing Guidance - Embodiments are directed towards providing method for negotiating a license to a media item by a customer for a commercial use, including maintaining by a digital media licensing server a catalog of media items that are available to be licensed, and a database of records. Receiving a designation of a media item from the catalog, providing a customer interface that enables a customer to specify an offer to license the selected media item; receiving an offer, electronically providing to a plurality of rights holders in the media item information about the offer, receiving from rights holders at least one counteroffer price, determining a collaborative counteroffer price, and providing the collaborative counteroffer price to the customer. Additional embodiments are directed toward a method for making recommendations for alternative media items to license. | 04-25-2013 |
20150213486 | Method and Device For Placing Branded Products As Advertisements Within Media - Embodiments are directed towards providing a computer-implemented method for integrating or placing branded product advertisement within media, including maintaining by a placement server a database of placement opportunities, receiving from a buyer computer a media plan by a buyer, the media plan specifying desired placements to purchase and a budget, projecting the number of impressions the purchased placements will generate, initiating execution of the media plan, gathering data about the results of each of the purchased and produced placements, determining a placement quality ranking for each placement and estimating a media value for each placement. | 07-30-2015 |
20150278894 | Management And Brokering Of The Purchase of Placements Over A Network - Embodiments are directed towards providing a computer-implemented method for negotiating the purchase of a placement that communicates a rights holder interface over a network to a rights holder for dynamically accessing terms of an offer, the offer based at least in part on a request by a rights requester to purchase a placement controlled by the rights holder, wherein the rights holder interface includes a control accessible to the rights holder for dynamically revising terms of the offer, receives from the rights holder over the network a counteroffer that includes an indication of a revision by the rights holder to at least one of the terms of the offer, evaluates the counteroffer received from the rights holder and determines that the terms of the counteroffer, including the at least one revised term, are acceptable; and communicates a confirmation of the counteroffer to the rights holder. | 10-01-2015 |
Patent application number | Description | Published |
20080201847 | PATIENT SUPPORT APPARATUS HAVING A DIAGNOSTIC SYSTEM - A patient support including a frame and a mattress supported by the frame. The frame includes a deck support and a deck supporting the mattress. | 08-28-2008 |
20080201851 | LIFT SYSTEM FOR HOSPITAL BED - A lift system for a hospital bed is disclosed. The lift system includes lift arms that support a frame over a base frame. The lift arms are moved to raise and lower the frame relative to the base frame. | 08-28-2008 |
20080289108 | LIFT SYSTEM FOR HOSPITAL BED - A lift system for a hospital bed is disclosed. The lift system includes lift arms that support a frame over a base frame. The lift arms are moved to raise and lower the frame relative to the base frame. | 11-27-2008 |
20090313758 | HOSPITAL BED - A hospital bed is disclosed. The bed includes at least one tiltable deck section, and a linkage assembly configured to facilitate tilting of the at least one deck section. | 12-24-2009 |
20100122412 | Bed and Vertically Compact Side Barrier Therefor - Side barrier retractable bed made up of parallel bars (e.g. | 05-20-2010 |
20120174319 | Hospital Bed - A patient support includes a frame and a mattress supported by the frame. The frame includes a deck support and a deck supporting the mattress. | 07-12-2012 |
20140020175 | MONITORING SYSTEMS DEVICES AND METHODS FOR PATIENT LIFTS - A monitoring system comprises a lift assembly configured to lift a patient; a control system configured to control operation of the lift system; and a reporting system in communication with the control system and configured to receive operational information for the lift assembly. The reporting system compares the operational information to a predetermined set of values to determine if the operation of the lift is in compliance with the protocols. | 01-23-2014 |
20140165290 | Patient Support Apparatus Having Movable Handles - A patient support apparatus includes a rolling base, a push handle unit, and a siderail. The push handle unit is coupled to a head end of the rolling base to provide a hand hold for a user pushing the rolling base from along the head end of the rolling base. The siderail is extends along a side of the rolling base to provide a hand hold for a caregiver pushing the rolling base from along the side of the rolling base. | 06-19-2014 |
20150224005 | HOSPITAL BED - A patient support includes a frame and a mattress supported by the frame. The frame includes a deck support and a deck supporting the mattress. | 08-13-2015 |
Patent application number | Description | Published |
20090203698 | Compounds for Enzyme Inhibition - Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles. | 08-13-2009 |
20100144648 | COMPOUNDS FOR ENZYME INHIBITION - One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention. | 06-10-2010 |
20100144649 | COMPOUNDS FOR ENZYME INHIBITION - One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention. | 06-10-2010 |
20120088762 | COMPOUNDS FOR ENZYME INHIBITION - One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention. | 04-12-2012 |
20120101025 | Compounds For Enzyme Inhibition - Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. | 04-26-2012 |
20120101026 | Compounds For Enzyme Inhibition - Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. | 04-26-2012 |
20130035297 | COMPOUNDS FOR ENZYME INHIBITION - One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention. | 02-07-2013 |
20130041008 | COMPOUNDS FOR ENZYME INHIBITION - One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention. | 02-14-2013 |
20130072422 | COMPOUNDS FOR IMMUNOPROTEASOME INHIBITION - One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention. | 03-21-2013 |
20130130968 | COMPOUNDS FOR ENZYME INHIBITION - Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles. | 05-23-2013 |
20130338057 | COMPOUNDS FOR ENZYME INHIBITION - One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention. | 12-19-2013 |
20140031297 | COMPOUNDS FOR ENZYME INHIBITION - Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles. | 01-30-2014 |
20140050737 | COMPOUNDS FOR ENZYME INHIBITION - Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles. | 02-20-2014 |
20140051641 | COMPOUNDS FOR ENZYME INHIBITION - Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles. | 02-20-2014 |
20140080753 | COMPOUNDS FOR ENZYME INHIBITION - One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention. | 03-20-2014 |
20140100169 | COMPOUNDS FOR ENZYME INHIBITION - One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention. | 04-10-2014 |
Patent application number | Description | Published |
20090156535 | MicroRNAs for Modulating Herpes Virus Gene Expression - An algorithm for identification of microRNA (miRNA) targets within viral and cellular RNA is disclosed. Also disclosed are essential herpes virus genes whose transcripts contain one or more targets of miRNAs encoded by herpes viruses or by host cells as predicted by the algorithm, and the use of such targets, miRNAs and their derivatives for modulating viral replication and latency. | 06-18-2009 |
20090239830 | Treatment of viral infections by modulation of host cell metabolic pathways - Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated. | 09-24-2009 |
20100285059 | Cytomegalovirus Vaccines and Methods of Production - Methods of increasing diversity in cytomegalovirus vaccines through the selection of cell type in which the virus is propagated, and the use of cytomegalovirus produced by those methods in the development of vaccine compositions, are disclosed. Vaccine compositions comprising CMV isolated from epithelial cells are also disclosed. | 11-11-2010 |
20110200633 | Cytomegalovirus Surface Protein Complex for Use in Vaccines and as a Drug Target - Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pUL128 or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection. | 08-18-2011 |
20120184600 | Inhibition of Glycerol-3-Phosphate Acyltransferase (GPAT) and Associated Enzymes for Treatment of Viral Infections - A method of treating or preventing a viral infection in a mammal by administering a compound or pharmaceutically acceptable derivative thereof that inhibits a phosphatidic acid synthesis enzyme | 07-19-2012 |
20120190676 | INHIBITORS OF MTOR KINASE AS ANTI-VIRAL AGENTS - The present invention provides methods and compositions for treating or preventing viral infections using modulators of host cell enzymes relating to mTOR. The invention also provides methods and compositions for treating or preventing viral infections using modulators of host cell enzymes relating to mTOR and modulators of the unfolded protein response. | 07-26-2012 |
20120226023 | CYTOMEGALOVIRUS SURFACE PROTEIN COMPLEX FOR USE IN VACCINES AND AS A DRUG TARGET - Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pUL128 or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection. | 09-06-2012 |
20130065850 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS - Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) in order to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, as well as in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. The antiviral activity of enzyme inhibitors is demonstrated. | 03-14-2013 |
20130190381 | INHIBITORS OF LONG AND VERY LONG CHAIN FATTY ACID METABOLISM AS BROAD SPECTRUM ANTI-VIRALS - The present invention provides methods and compounds for treating viral infections using modulators of host cell enzymes relating to long chain fatty acid and lipid droplet metabolism. It includes a method of treating viral infections using triacsin C and its relatives, analogues and derivatives as well as other inhibitors of long chain fatty acid metabolism and lipid droplet metabolism. | 07-25-2013 |
20130338178 | SIRTUIN MODULATORS AS INHIBITORS OF CYTOMEGALOVIRUS - Agents and methods of inhibiting or improving the growth of viruses are provided. | 12-19-2013 |
20140018354 | INHIBITORS OF MTOR KINASE AS ANTI-VIRAL AGENTS - The present invention provides methods and compositions for treating or preventing viral infections using modulators of host cell enzymes relating to mTOR. The invention also provides methods and compositions for treating or preventing viral infections using modulators of host cell enzymes relating to mTOR and modulators of the unfolded protein response. | 01-16-2014 |
20140113353 | Method to Produce Virus in Cultured Cells - A method for improving virus production in a host cell infected with the virus is provided. | 04-24-2014 |
20140206678 | INHIBITORS OF MTOR KINASE AS ANTI -VIRAL AGENT - The present invention provides methods for treating or preventing viral infections using modulators of host cell enzymes relating to mTOR. The invention also provides methods for treating or preventing viral infections using modulators of host cell enzymes relating to mTOR and modulators of the unfolded protein response. | 07-24-2014 |
20140212950 | METHOD TO INCREASE THE INFECTIVITY OF VIRUS PARTICLES - A method for enhancing infectivity of HCMV virus particles is provided. | 07-31-2014 |
20140370026 | Cytomegalovirus Surface Protein Complex For Use in Vaccines and as a Drug Target - Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130 are described. Also disclosed are therapeutic antibodies reactive against a CMV protein complex comprising pULl28or pUL130, as well as methods for screening compounds that inhibit CMV infection of epithelial and endothelial cells, methods for immunizing a subject against CMV infection, methods for determining the capability of neutralizing antibodies to inhibit CMV infection of cell types other than fibroblasts, and methods of diminishing an CMV infection. | 12-18-2014 |
20150240215 | METHOD TO PRODUCE VIRUS IN CULTURED CELLS SUPPLEMENTED WITH ALPHA-KETOGLUTARATE - The present disclosure provides a method to enhance the production of virus in cultured fibroblasts by supplementing the cells with a TCA cycle intermediate, aketoglutarate, or a derivative thereof, wherein virus production is enhanced compared to the same method canied out in the absence of a-ketoglutarate or the derivative thereof. In view of the art, the method provides an unexpected improvement on methods routinely practiced. | 08-27-2015 |
20150335657 | Methods for Modulating Sirtuin Enzymes - This document relates to compounds useful for modulating sirtuin enzymes. For example, the compounds provided herein are useful as broad spectrum antiviral agents. In addition, the compounds provided herein may be used in the treatment of other disorders associated with sirtuin enzymes, such as diseases related to aging and stress, blood clotting disorders, cancer, cardiovascular diseases, diabetes, inflammation, neurodegenerative diseases, and obesity. | 11-26-2015 |